By shifting the paradigm from "drug resistance" to "tolerance modulation, " this review provides a strategic roadmap for harnessing CRL-targeted interventions to restore immune homeostasis and sensitize HCC to immunotherapy. The gene discussed is IL31RA; the disease is hepatocellular carcinoma.